Skip to main content

and
  1. No Access

    Article

    The Impact of Glycosylation on the Pharmacokinetics of a TNFR2:Fc Fusion Protein Expressed in Glycoengineered Pichia Pastoris

    P. pastoris has previously been genetically engineered to generate strains that are capable of producing mammalian-like glycoforms. Our objective was to investigate the correlation bet...

    Liming Liu, Sujatha Gomathinayagam, Lora Hamuro in Pharmaceutical Research (2013)

  2. No Access

    Article

    High-throughput screening and selection of yeast cell lines expressing monoclonal antibodies

    The methylotrophic yeast Pichia pastoris has recently been engineered to express therapeutic glycoproteins with uniform human N-glycans at high titers. In contrast to the current art where producing therapeutic p...

    Gavin C. Barnard, Angela R. Kull in Journal of Industrial Microbiology & Biote… (2010)

  3. No Access

    Protocol

    Characterization of N-Linked Glycosylation on Recombinant Glycoproteins Produced in Pichia pastoris Using ESI-MS and MALDI-TOF

    The production of recombinant therapeutic glycoproteins is an active area of research and drug development. Typically, improvements in therapeutic glycoprotein efficacy have focused on engineering additional N...

    Bing Gong, Michael Cukan, Richard Fisher, Huijuan Li, Terrance A. Stadheim in Glycomics (2009)

  4. No Access

    Article

    Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response

    Traditional production of therapeutic glycoproteins relies on mammalian cell culture technology. Glycoproteins produced by mammalian cells invariably display N-glycan heterogeneity resulting in a mixture of gl...

    Byung-Kwon Choi, Jeffrey K. Actor, Sandra Rios, Marc d’Anjou in Glycoconjugate Journal (2008)